SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-004563
Filing Date
2018-05-10
Accepted
2018-05-10 06:49:07
Documents
58
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20180331x10q.htm 10-Q 1288538
2 EX-31.1 syrs-20180331ex31153e52a.htm EX-31.1 10240
3 EX-31.2 syrs-20180331ex31238c9a6.htm EX-31.2 10775
4 EX-32.1 syrs-20180331ex321237dde.htm EX-32.1 7441
5 EX-32.2 syrs-20180331ex322072cf9.htm EX-32.2 7444
  Complete submission text file 0001558370-18-004563.txt   5077559

Data Files

Seq Description Document Type Size
6 EX-101.INS syrs-20180331.xml EX-101.INS 994115
7 EX-101.SCH syrs-20180331.xsd EX-101.SCH 41771
8 EX-101.CAL syrs-20180331_cal.xml EX-101.CAL 39257
9 EX-101.DEF syrs-20180331_def.xml EX-101.DEF 161313
10 EX-101.LAB syrs-20180331_lab.xml EX-101.LAB 386231
11 EX-101.PRE syrs-20180331_pre.xml EX-101.PRE 289191
Mailing Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 18820417
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences